Cannabidiol (CBD) and metformin can alleviate behavioral difficulties in mouse models of Fragile X and Phelan-McDermid syndromes. Both conditions, linked to autism spectrum disorder, saw improvements in speech, social interactions, and repetitive behaviors. This promising study paves the way for potential new treatments with minimal side effects. Ongoing clinical trials aim to confirm these findings in humans.
